New oral drugs for erectile dysfunction
Relevant BNF section: 7.4.5
In 1998, we concluded that sildenafil (Viagra - Pfizer Ltd), a selective phosphodiesterase type 5 inhibitor, appeared to offer advantages over other medical approaches for erectile dysfunction in terms of ease of administration and cost.1 Oral drug treatment is now widely advocated as first-line therapy for erectile dysfunction,2 except where the cause is clearly psychological. In the past 4 years, three more oral preparations have been licensed in the UK for the treatment of men with erectile dysfunction. A sublingual preparation of the dopaminergic agonist
apomorphine (Uprima - Abbott Laboratories Ltd) is the first centrally acting drug to be licensed.
Tadalafil (Cialis - Eli-Lilly) and
vardenafil (Levitra - Bayer PLC) are phosphodiesterase type 5 inhibitors. Here we review the place of these preparations for men with erectile dysfunction.
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
